MAVENIR
20.2.2024 08:01:34 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks, announces new developments on its OpenBeam™ massive MIMO (mMIMO) portfolio, powered by Qualcomm® QRU100 5G RAN platform, in continuation to previous years product launch update. Mavenir expands the OpenBeam™ portfolio by introducing the low-power next-generation 32TRX mMIMO variant along with a high-power 32TRX AAU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240219034877/en/
Mavenir OpenBeam massive MIMO 32TRX Active Antenna Unit. (Photo: Business Wire)
These next-generation mMIMO 32TRX Active Antenna Units (AAUs) introduce a new breed of open and interoperable radios that are green by design. OpenBeam™ mMIMO AAU delivers exceptional energy efficiency – resulting in one of the leanest mMIMO AAU footprints in the industry, offering substantial OpEx savings.
In addition to the current O-RAN 7.2b specification, the products are also engineered to support ULPI (Uplink Performance Improvement), allowing network operators to improve uplink performance of massive MIMO, minimize latency, and reduce fronthaul bandwidth, especially in urban settings where network capacity demand is high.
The portfolio consists of two discrete models that accelerate 5G mid-band rollouts:
- 32TRX AAU low power model: Offering one of the lowest footprints in the industry, the low power mMIMO AAU delivers 200W output power with 128 antenna elements at the lowest energy consumption. The solution is optimized for deployment in dense environments, driving faster installations and lower operational overheads.
- 32TRX AAU high power model: Mavenir’s high-performance mMIMO AAU capable of delivering 320W output power and offering 192 antenna elements. This platform supports larger instantaneous bandwidth, while the output power extends coverage, making it ideal for RAN sharing deployments.
The 32TRX AAU solutions deliver advanced energy-saving capabilities incorporating smart sleep-mode schemes that are activated during idle, low, and busy hour traffic. These automated capabilities can be further enhanced using AI/ML-based intelligence.
Paco Martin, Head of Open RAN at Vodafone Group: “We are pleased to see the broadening of Mavenir’s mMIMO portfolio with the addition of a low power, compact product fitting our single-operator and footprint-constrained sites, on top of the existing higher power leading solution. Further adoption of Qualcomm QRU100 5G RAN Platform keeps bringing high performance and power efficient Open RAN radios allowing us to deliver the best customer experience.”
BG Kumar, President, Access Networks, Platforms and MDE from Mavenir said: “With this continuing evolution and enhancement of our OpenBeam™ massive MIMO radio solutions, Mavenir is once again setting new standards in the industry for energy efficiency, sustainability and performance.”
“We are very pleased with this extension to Mavenir’s portfolio of high performing and power efficient Massive MIMO Radios, powered by Qualcomm QRU100 5G RAN Platform,” said Gerardo Giaretta, Vice President, Product Management, Qualcomm Technologies, Inc. “This is another great milestone in our ongoing collaboration with Mavenir, driving full-scale adoption of Open and Virtualized RAN.”
Mavenir’s OpenBeam™ full radio portfolio will be displayed at the upcoming Mobile World Congress in Barcelona, Feb 26-29, in Hall 2 Stand 2H60. For more on Mavenir’s presence at the show visit www.mavenir.com/mwc-2024
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 300+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
For more information, please visit www.mavenir.com
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240219034877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom